Study of 400mcg Sublingual Versus 400mcg Buccal Misoprostol Following 200mg Mifepristone for Medical Abortion up to 63 Days Last Menstrual Period (LMP)
Study of 400mcg Sublingual Versus 400mcg Buccal Misoprostol Following 200mg Mifepristone for Medical Abortion up to 63 Days Last Menstrual Period (LMP)
This open-label, randomized study is being conducted to determine whether a dose of 400 mcg
 of buccal misoprostol (i.e., in the cheek) taken 24 hours following administration of
 mifepristone 200 mg is as effective and acceptable at inducing an abortion compared with
 misoprostol taken sublingually (under the tongue). Women presenting for voluntary termination
 of intrauterine pregnancy with gestational ages of <63 days will be offered the option of
 participating in the study.
Inclusion Criteria:

 -  Gestational age less than or equal to 63 days

 -  General good health including absence of conditions which contraindicate the use of
 mifepristone and misoprostol for pregnancy termination; and

 -  Willing to provide an address and/or telephone number for purposes of follow-up.

 Exclusion Criteria:

 -  Confirmed or suspected ectopic pregnancy or undiagnosed adnexal mass

 -  IUD in place

 -  Chronic renal failure

 -  Concurrent long-term corticosteroid therapy

 -  History of allergy to mifepristone, misoprostol or other prostaglandin

 -  Hemorrhagic disorders or concurrent anticoagulant